Nevertheless, timely administration of SMN gene replacement prevents the rapid clinical deterioration normally observed in untreated patients with SMA type 1, likely by preventing denervation of motor units within the first 3 postnatal months33. Here, SMN1 is linked to spinal muscular atrophy, type 1.